Aktis Oncology (NASDAQ:AKTS) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Aktis Oncology (NASDAQ:AKTS) to a hold rating in a research report sent to investors on Saturday morning.

Aktis Oncology Trading Down 3.9%

NASDAQ:AKTS opened at $19.75 on Friday. Aktis Oncology has a fifty-two week low of $19.02 and a fifty-two week high of $29.16.

Insider Buying and Selling

In other news, major shareholder Vida Ventures Ii, Llc acquired 835,000 shares of the firm’s stock in a transaction on Monday, January 12th. The stock was acquired at an average price of $18.00 per share, with a total value of $15,030,000.00. Following the completion of the purchase, the insider directly owned 5,671,825 shares in the company, valued at approximately $102,092,850. This trade represents a 17.26% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Bioventures 2018 L.P. Mpm bought 1,112,777 shares of the company’s stock in a transaction on Monday, January 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $20,029,986.00. Following the transaction, the insider directly owned 10,260,064 shares of the company’s stock, valued at approximately $184,681,152. This trade represents a 12.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders bought a total of 6,117,776 shares of company stock worth $110,119,968 over the last three months.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.